在第三阶段试验中,创新生物生物学家的马祖底德(Mazdutide)在控制中国2型糖尿病患者的血糖和减肥方面优于杜拉格卢底德(Dulaglutide)的表现。 Innovent Biologics' Mazdutide outperforms Dulaglutide in controlling blood sugar and reducing weight in Chinese type 2 diabetes patients in a Phase 3 trial.

创新生物公司的第三期试验DREAMS-2显示,Mazdutide是双GLP-1R和GCGR激动剂,在控制血糖和减肥方面优于Dulaglutide,在中国的2型糖尿病患者中. Innovent Biologics' Phase 3 trial DREAMS-2 shows Mazdutide, a dual GLP-1R and GCGR agonist, outperforms Dulaglutide in controlling blood sugar and reducing weight in Chinese type 2 diabetes patients. 超过28周,Mazdutide(Mazdutide)导致HbA1c(最大1.73%)和体重减少(最高9.24%)的减少幅度更大。 Over 28 weeks, Mazdutide led to greater HbA1c reductions (up to 1.73%) and weight loss (up to 9.24%). 该药物还改善了心肺新陈代谢风险因素,其安全情况与以往的研究一致,主要是轻微肠胃副作用。 The drug also improved cardiometabolic risk factors, with a safety profile consistent with previous studies, primarily mild gastrointestinal side effects.